Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04054544 · ClinicalTrials.gov registry record · Early Phase 1
Gluten Challenge Study in Celiac Disease Participants (MK-0000-402)
A Early Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 18
- Enrollment target
NCT04054544 is a Early Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 18 participants.
The verdict
NCT04054544, a Early Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This is a gluten challenge study to characterize peripheral blood and intestinal gluten specific cluster of differentiation 4 glycoprotein (CD4+) thymus lymphocyte (T cell) subsets in participants with Celiac Disease
Interventions
- DIETARY_SUPPLEMENT Gluten powder 4g
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2020-08-28 |
| Est. Completion | 2021-06-23 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04054544
The ClinicalTrials.gov registry entry for NCT04054544 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gluten powder 4g is the first listed.
NCT04054544 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04054544 about?
NCT04054544 is a clinical study titled "Gluten Challenge Study in Celiac Disease Participants (MK-0000-402)". This is a gluten challenge study to characterize peripheral blood and intestinal gluten specific cluster of differentiation 4 glycoprotein (CD4+) thymus lymphocyte (T cell) subsets in participants with Celiac Disease
What is the current status of trial NCT04054544?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 18 participants. The study started on 2020-08-28. Estimated completion is 2021-06-23.
What interventions are being tested in trial NCT04054544?
The interventions under investigation include: Gluten powder 4g (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04054544?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.